Shares of Xencor Inc (NASDAQ:XNCR) have received an average recommendation of “Buy” from the nine research firms that are presently covering the firm. Three research analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $29.33.
Several brokerages have commented on XNCR. Zacks Investment Research raised Xencor from a “hold” rating to a “buy” rating and set a $29.00 price objective on the stock in a research report on Saturday, March 4th. Wedbush reaffirmed an “outperform” rating and issued a $33.00 price objective (up previously from $27.00) on shares of Xencor in a research report on Thursday, March 2nd. Instinet began coverage on Xencor in a research report on Wednesday, March 1st. They issued a “neutral” rating and a $21.00 price objective on the stock. Nomura began coverage on Xencor in a research report on Wednesday, March 1st. They issued a “neutral” rating on the stock. Finally, TheStreet raised Xencor from a “sell” rating to a “hold” rating in a research report on Friday, December 2nd.
Xencor (NASDAQ:XNCR) traded down 0.73% during trading on Monday, hitting $24.35. The stock had a trading volume of 80,343 shares. Xencor has a 52-week low of $10.95 and a 52-week high of $29.38. The stock has a market capitalization of $1.13 billion, a PE ratio of 43.48 and a beta of 2.21. The stock’s 50-day moving average is $24.25 and its 200-day moving average is $24.03.
In other news, VP John J. Kuch sold 15,000 shares of the stock in a transaction on Thursday, March 16th. The stock was sold at an average price of $24.42, for a total transaction of $366,300.00. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Edgardo Baracchini, Jr. sold 1,821 shares of the stock in a transaction on Wednesday, March 8th. The stock was sold at an average price of $25.00, for a total value of $45,525.00. Following the transaction, the insider now directly owns 1,821 shares in the company, valued at approximately $45,525. The disclosure for this sale can be found here. 4.03% of the stock is currently owned by corporate insiders.
Institutional investors have recently bought and sold shares of the company. Perceptive Advisors LLC purchased a new position in Xencor during the fourth quarter worth about $46,982,000. BlackRock Fund Advisors increased its position in Xencor by 5.5% in the third quarter. BlackRock Fund Advisors now owns 1,437,156 shares of the biopharmaceutical company’s stock worth $35,196,000 after buying an additional 74,735 shares during the last quarter. Baker BROS. Advisors LP purchased a new position in Xencor during the third quarter worth about $21,357,000. State Street Corp increased its position in Xencor by 7.5% in the fourth quarter. State Street Corp now owns 844,845 shares of the biopharmaceutical company’s stock worth $22,234,000 after buying an additional 58,629 shares during the last quarter. Finally, Orbimed Advisors LLC increased its position in Xencor by 12.9% in the fourth quarter. Orbimed Advisors LLC now owns 840,237 shares of the biopharmaceutical company’s stock worth $22,115,000 after buying an additional 95,715 shares during the last quarter. 64.14% of the stock is currently owned by institutional investors and hedge funds.
Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. Its segment is related to the development of pharmaceutical products. It uses its XmAb technology platform to create antibody product candidates designed to treat autoimmune and allergic diseases, cancer and other conditions.
Receive News & Ratings for Xencor Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor Inc and related companies with MarketBeat.com's FREE daily email newsletter.